Navigation Links
Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development

Please see this announcement regarding a new partnership among 2 leading service providers to the world-wide biopharmaceutical industry. Quintiles, the world's largest leading CRO has selected invivodata to be its preferred provider for electronic Patient Reported Outcomes (ePRO) solutions and services.

Research Triangle Park, N.C., and Pittsburgh, PA (Vocus) January 18, 2010 -- Quintiles, the world’s leading biopharmaceutical services company, and invivodata, inc., an industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a collaboration agreement to transform the way Patient Reported Outcomes (PRO) are used in clinical research to speed drug development.

The collaborative arrangement connects invivodata’s PRO consulting, technology, and service solutions to the full suite of Quintiles’ clinical services, providing integrated processes and deliverables, It will reduce study complexity and cost as redundant services are removed throughout all phases of drug development.

“Regulators, especially the FDA, have increased the pressure on drug developers to focus on the patient’s perspective regarding drug effects, and Quintiles is working with customers to effectively manage this changing environment,” said Paula Brown Stafford, Executive Vice President, Integrated Clinical Services for Quintiles. “While the patient perspective can be obtained in various ways, real-time PRO data are common measures of drug efficacy, and ePRO is an accurate and reliable way to capture these data. Quintiles has led the CRO market place in providing electronic data capture services and ePRO is a logical extension of that leadership for our customers.

“Our collaboration with invivodata will provide handheld technology that drives high patient compliance and meets the needs of the ever-evolving regulatory guidelines. After a thorough evaluation, we found invivodata’s combination of science-based methodologies and innovative technology coupled with a collaborative approach to partnering in global support services to be a complement to Quintiles’ strategic vision for PRO,” added Stafford.

The agreement solidifies an ongoing collaborative effort between the companies, with invivodata providing its ePRO solutions in more than 20 joint studies to date.

“Quintiles’ vision for the implementation of eClinical solutions continues to deliver tangible value to study sponsors. We are very excited to formalize what has been a mutually beneficial collaborative effort over the past few years. We take great pride in our commitment to strong business partnerships that deliver real value to both sides and especially to sponsors. With our ongoing innovation around ePRO technology and the growing demand for our PRO consulting services, we see a nice fit into Quintiles’ approach to serving customers, and we view this relationship as a key step in driving the ePRO market forward,” commented Doug Engfer, co-founder and CEO of invivodata.

About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit

About invivodata inc.
invivodata combines behavioral science, information technology and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit

# # #

Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Quintiles Recognized Among Best Companies to Work For in Brazil
2. Quintiles Expands Base for Growing Asia-Pacific Operations
3. Quintiles Named to Computerworld Magazines 100 Best Places to Work in Information Technology List
4. Quintiles Appoints New Executives
5. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
6. Quintiles Signs Agreement to Acquire Eidetics
7. Quintiles Consulting Business Expands
8. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
9. Quintiles to Open Clinical Research Office in Wilmington, NC
10. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
11. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
Post Your Comments:
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Twist ... announced that Emily Leproust, Ph.D., Twist Bioscience chief ... Jaffray Healthcare Conference on December 1, 2015 at ... Hotel in New York City. --> ... . Twist Bioscience is on Twitter. ...
(Date:11/24/2015)... -- Capricor Therapeutics, Inc. (NASDAQ: CAPR ... and commercialization of first-in-class therapeutics, today announced that ... to present at the 2015 Piper Jaffray Healthcare Conference ... The Lotte New York Palace Hotel in ... --> . --> ...
(Date:11/24/2015)... According to two new studies, fewer men are having PSA ... doctors, scientists, and public health experts have been pushing for ... being done, will there be more men dying of ... "Despite the efforts made in regards to early detection for ... of death in men, killing approximately 27,500 men this year. ...
(Date:11/23/2015)... ... 23, 2015 , ... Noblis, Inc., a leading provider of science, technology, and ... Geospatial Intelligence Agency (NGA), has joined the Noblis NSP team as President of the ... intelligence community and the private sector,” said L. Roger Mason, Jr., Ph.D. , ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/17/2015)... Paris from 17 th until 19 th ... from 17 th until 19 th November 2015.   ... the first combined scanner in the world which scans both ... two different scanners were required: one for passports and one ... same surface. This innovation is an ideal solution for electronic ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
Breaking Biology News(10 mins):